First American Bank Decreases Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

First American Bank lowered its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 10.9% in the third quarter, HoldingsChannel.com reports. The firm owned 19,223 shares of the company’s stock after selling 2,340 shares during the quarter. First American Bank’s holdings in AstraZeneca were worth $1,498,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of AZN. Valley National Advisers Inc. increased its holdings in shares of AstraZeneca by 6,460.6% in the 3rd quarter. Valley National Advisers Inc. now owns 22,962 shares of the company’s stock valued at $1,788,000 after acquiring an additional 22,612 shares during the last quarter. Smith Salley Wealth Management boosted its holdings in AstraZeneca by 1.0% in the third quarter. Smith Salley Wealth Management now owns 16,158 shares of the company’s stock valued at $1,259,000 after purchasing an additional 162 shares in the last quarter. Boston Trust Walden Corp increased its stake in AstraZeneca by 13.0% in the third quarter. Boston Trust Walden Corp now owns 6,166 shares of the company’s stock valued at $480,000 after purchasing an additional 711 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in AstraZeneca by 3.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 191,741 shares of the company’s stock worth $14,939,000 after purchasing an additional 5,589 shares in the last quarter. Finally, Pathway Financial Advisers LLC lifted its position in shares of AstraZeneca by 7,690.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 22,126 shares of the company’s stock worth $1,724,000 after buying an additional 21,842 shares during the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $75.05 on Monday. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The stock has a market capitalization of $232.70 billion, a price-to-earnings ratio of 36.26, a PEG ratio of 1.39 and a beta of 0.46. The company has a 50-day simple moving average of $80.40 and a 200-day simple moving average of $78.59. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.01. The company had revenue of $12.45 billion for the quarter, compared to the consensus estimate of $12.62 billion. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The company’s revenue was up 9.1% on a year-over-year basis. During the same period last year, the business posted $1.08 EPS. On average, analysts predict that AstraZeneca PLC will post 4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AZN. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. TD Cowen raised their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a report on Friday, September 13th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.